Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro has surpassed Merck & Co.’s cancer therapy Keytruda as the world’s ...

Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.

Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to ...

The Department of Health (DoH) said it is "aware" of the jab and is "exploring" how it can be made available to patients in ...

Merck (NYSE:MRK | MRK Price Prediction) delivered its fourth consecutive earnings beat, but shares slipped on the earnings ...

Patients in East Yorkshire and North Lincolnshire are set to benefit from quicker treatment.

First approved by the US FDA in 2014 for advanced skin cancer, Keytruda is now used globally for certain lung cancers, cervical cancer, renal cell cancer and aggressive breast cancer, among others.

One day after a double-pronged loss in prostate and lung cancer, Merck & Co.’s immuno-oncology superstar Keytruda is bouncing back. In the phase 3 Keynote-671 study, Keytruda hit one of two primary ...

A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal cell carcinoma trial.

Mounjaro generated $8.7 billion for Lilly in the first quarter of 2026, outperforming Merck's Keytruda, which posted sales of ...